Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 96, Issue 1, 2011, Pages

  Jones, Lisa J ^a,b   Craven, P D ^a,b   Attia, J ^b,c   Thakkinstian, A ^b   Wright, I ^a,b  

^a JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; INDOMETACIN;

ARTICLE; BRAIN HEMORRHAGE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEWBORN DEATH; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78650810279     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2009.168682     Document Type: Article

References (42)

1. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88:192-201.
2. Meyers RL, Alpan G, Lin E, et al. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 1991;29:569-74.
3. Corazza MS, Davis RF, Merritt TA, et al. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr 1984;105:292-6.
4. Miller SP, Mayer EE, Clyman RI, et al. Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth. Pediatrics 2006;117:1626-31.
5. Van Bel F, Van de Bor M, Stijnen T, et al. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics 1989;84:802-7.
6. van Bel F, Guit GL, Schipper J, et al. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991;118:621-6.
7. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;1:CD004213.
8. Amin SB, Handley C, Carter-Pokras O. Indomethacin use for the management of patent ductus arteriosus in preterms: a web-based survey of practice attitudes among neonatal fellowship program directors in the United States. Pediatr Cardiol 2007;28:193-200.
9. Hoellering AB, Cooke L. The management of patent ductus arteriosus in Australia and New Zealand. J Paediatr Child Health 2009;45:204-9.
10. Fowlie PW, Davis PW. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002;3:CD000174.
11. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008;1:CD003481.
12. Knight D. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001;6:63-73.
13. Nehgme R, O'Connor T, Lister G, et al. Patent ductus arteriosus. In: Sinclair J, Bracken MB, eds. Effective care of the newborn infant. Oxford: Oxford University Press, 1992:305-16.
14. Bayley N. Manual for the Bayley scales of infant development. 2nd edn. San Antonio (TX): The Psychological Corporation, 1993.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
16. Glenny AM, Altman DG, Song F, et al.; International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv.
17. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
18. Thakkinstian A, McEvoy M, Minelli C, et al. Systematic review and metaanalysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005;162:201-11.
19. StataCorp. Stata Statistical Software: Release 10. College Station (TX): StataCorp LP, 2007.
20. Review Manager (RevMan) [computer program] Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
21. Plavka R, Svihovec P, Borek I, et al. Ibuprofen vs. indomethacin in the treatment of patent ductus arteriosus (PDA) in very premature neonates (English abstract). Pediatr Res 2001;49:375A.
22. Van Overmeire B, Follens I, Hartmann S, et al. Intravenous ibuprofen (IBU) for the treatment of patent ductus arteriosus (PDA) in preterm infants with respiratory distress syndrome (RDS). Pediatr Res 1996;39:250A.
23. Adamska E, Helwich E, Rutkowska M, et al. Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants (In Polish). Med Wieku Rozwoj 2005;9:335-54.
24. Gimeno Navarro A, Cano Sánchez A, Fernández Gilino C, et al. Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants (In Spanish). An Pediatr (Barc) 2005;63:212-8.
25. Monset-Couchard M, Dias-Mançano D, Murat I, et al. Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants (In French). Pediatrie 1983;38:365-77.
26. Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.
27. Patel J, Roberts I, Azzopardi D, et al. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000;47:36-42.
28. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343:674-81.
29. Weesner KM, Dillard RG, Boyle RJ, et al. Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome. South Med J 1987;80:706-8.
30. Yeh TF, Luken JA, Thalji A, et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus-a double-blind controlled study. J Pediatr 1981;98:137-45.
31. Hammerman C, Strates E, Komar K, et al. Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant. Dev Pharmacol Ther 1987;10:393-404.
32. Mahony L, Carnero V, Brett C, et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982;306:506-10.
33. Krauss AN, Fatica N, Lewis BS, et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. Am J Dis Child 1989;143:78-81. (Pubitemid 19027271)
34. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002;161:202-7.
35. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997;131:549-54. (Pubitemid 28006927)
36. Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999;135:733-8.
37. Su PH, Chen JY, Su CM, et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003;45:665-70.
38. Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 1997;76:F179-84.
39. McCurnin D, Seidner S, Chang LY, et al. Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 2008;121:945-56.
40. Merritt TA, Harris JP, Roghmann K, et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. J Pediatr 1981;99:281-6.
41. Yeh TF, Goldbarg HR, Henek T, et al. Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up. Am J Dis Child 1982;136:803-7.
42. Peckham GJ, Miettinen OS, Ellison RC, et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. J Pediatr 1984;105:285-91.